Key Highlights
- Neuraxis will issue approximately 80,463 shares of common stock as a dividend for its Series B preferred stockholders.
- The dividend calculation divides accrued unpaid dividends by $2.38 per share to determine common stock distribution.
- Payment will occur in mid-2026, with a record date set for later in the same period.
- Fractional shares will be settled in cash at a rate equal to the product obtained by multiplying $2.38.
Dividend Structure Explained
The distribution will consist of common shares issued to preferred stockholders. The total number of shares to be distributed is approximately 80,463, representing the company’s effort to align its capital structure with shareholder returns. This approach allows Neuraxis to manage its preferred stock commitments while providing liquidity to investors.
Calculation Method
The number of common shares each preferred stockholder receives will be based on accrued and unpaid dividends. The formula divides these dividends by $2.38 to establish the share count. This method ensures a consistent and transparent conversion process for all eligible shareholders.
Record and Payment Dates
The record date for determining eligible stockholders will be established in the coming months, with the dividend payment following shortly thereafter. Investors must hold the Series B Preferred Stock by the record date to participate in the distribution. The company has not yet finalized the exact timing but expects the process to conclude in mid-2026.
Fractional Share Handling
Neuraxis will not issue partial shares. Instead, any fractional entitlement will be converted into a cash payment. The cash amount will equal the product obtained by multiplying the fractional share by $2.38.
This policy simplifies the distribution process while ensuring shareholders receive fair compensation.
Preferred Stock Terms
The Series B Preferred Stock remains unchanged in its core terms following this dividend. The conversion of accrued dividends into common stock does not modify the preferred stock’s par value or other contractual provisions. Investors should review the stock’s terms to understand their rights and obligations.
Regulatory Compliance
The dividend declaration adheres to the Securities Exchange Act of 1934 and other applicable U.S. Securities regulations. Neuraxis has filed the necessary disclosures to ensure compliance with transparency and investor protection standards.
The company’s approach reflects its commitment to maintaining regulatory best practices.
Investor Implications
The stock dividend may influence Neuraxis’s equity structure and market dynamics. Preferred stockholders should evaluate how the conversion affects their portfolio, including potential tax considerations and changes in ownership stakes. The shift from accrued dividends to common shares could also impact the company’s financial flexibility and shareholder liquidity.
The move aligns with broader trends in the biotechnology and life sciences sectors, where companies often balance capital efficiency with shareholder returns. Neuraxis’s decision to convert preferred dividends into common stock may signal its focus on optimizing its balance sheet while providing value to investors.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...